Amgen (AMGN)
(Delayed Data from NSDQ)
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.
Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 0.81% and 0.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EDOW
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.
Exploring Analyst Estimates for Amgen (AMGN) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
by Zacks Equity Research
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.
Amgen (AMGN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.
Amgen (AMGN) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $334.30 in the latest trading session, marking a -0.39% move from the prior day.
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
by Zacks Equity Research
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.